The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis.

Institut Curie, Centre de Recherche, F-75248 Paris, France.
Developmental Cell (Impact Factor: 10.37). 09/2011; 21(4):708-21. DOI: 10.1016/j.devcel.2011.08.019
Source: PubMed

ABSTRACT Cargo sorting to intraluminal vesicles (ILVs) of multivesicular endosomes is required for lysosome-related organelle (LRO) biogenesis. PMEL-a component of melanocyte LROs (melanosomes)-is sorted to ILVs in an ESCRT-independent manner, where it is proteolytically processed and assembled into functional amyloid fibrils during melanosome maturation. Here we show that the tetraspanin CD63 directly participates in ESCRT-independent sorting of the PMEL luminal domain, but not of traditional ESCRT-dependent cargoes, to ILVs. Inactivating CD63 in cell culture or in mice impairs amyloidogenesis and downstream melanosome morphogenesis. Whereas CD63 is required for normal PMEL luminal domain sorting, the disposal of the remaining PMEL transmembrane fragment requires functional ESCRTs but not CD63. In the absence of CD63, the PMEL luminal domain follows this fragment and is targeted for ESCRT-dependent degradation. Our data thus reveal a tight interplay regulated by CD63 between two distinct endosomal ILV sorting processes for a single cargo during LRO biogenesis.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Hedgehog signalling pathway is crucial for development, adult stem cell maintenance, cell migration and axon guidance in a wide range of organisms. During development, the Hh morphogen directs tissue patterning according to a concentration gradient. Lipid modifications on Hh are needed to achieve graded distribution, leading to debate about how Hh is transported to target cells despite being membrane-tethered. Cytonemes in the region of Hh signalling have been shown to be essential for gradient formation, but the carrier of the morphogen is yet to be defined. Here we show that Hh and its co-receptor Ihog are in exovesicles transported via cytonemes. These exovesicles present protein markers and other features of exosomes. Moreover, the cell machinery for exosome formation is necessary for normal Hh secretion and graded signalling. We propose Hh transport via exosomes along cytonemes as a significant mechanism for the restricted distribution of a lipid-modified morphogen.
    Nature Communications 12/2014; 5:5649. DOI:10.1038/ncomms6649 · 10.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Both normal and diseased cells continuously shed extracellular vesicles (EVs) into extracellular space, and the EVs carry molecular signatures and effectors of both health and disease. EVs reflect dynamic changes that are occurring in cells and tissue microenvironment in health and at a different stage of a disease. EVs are capable of altering the function of the recipient cells. Trafficking and reciprocal exchange of molecular information by EVs among different organs and cell types have been shown to contribute to horizontal cellular transformation, cellular reprogramming, functional alterations, and metastasis. EV contents may include tumor suppressors, phosphoproteins, proteases, growth factors, bioactive lipids, mutant oncoproteins, oncogenic transcripts, microRNAs, and DNA sequences. Therefore, the EVs present in biofluids offer unprecedented, remote, and non-invasive access to crucial molecular information about the health status of cells, including their driver mutations, classifiers, molecular subtypes, therapeutic targets, and biomarkers of drug resistance. In addition, EVs may offer a non-invasive means to assess cancer initiation, progression, risk, survival, and treatment outcomes. The goal of this review is to highlight the current status of information on the role of EVs in cancer, and to explore the utility of EVs for cancer diagnosis, prognosis, and epidemiology.
    BMC Clinical Pathology 04/2015; 15(1):6. DOI:10.1186/s12907-015-0005-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Cells release extracellular vesicles to their surroundings to communicate with each other. Exosomes are a subgroup of 30 – 100-nm-sized extracellular vesicles, originating from the endocytic pathway. They contain RNA molecules, proteins and lipids that can be transferred between cells. Exosomes have been found in several body fluids, indicating that this is a frequently used and tolerated system for cells to communicate RNA molecules and proteins over distances. Areas covered: It has been shown that patients with cancer have higher concentrations of exosomes in their blood and that these exosomes can carry tumor-specific molecules. Exosomes are, therefore, currently being evaluated for their potential use as biomarkers. Additionally, exosomes have been demonstrated to have the capacity to modulate immune responses. Therefore, exosomes are believed to be beneficial as a cell-free vaccine for cancer and infections. Further, as exosomes are the body’s endogenous system for transport RNA, exosomes are also evaluated for their potential use as a therapeutic RNA delivery system. This review provides an overview of studies reporting diagnostic and therapeutic potential for exosomes. Expert opinion: The data reviewed here suggest that exosomes have the potential to be used for both diagnosis and therapy for several diseases in the future. Read More:
    Expert Opinion on Biological Therapy 01/2015; 15(1):103-117. DOI:10.1517/14712598.2015.977250 · 3.65 Impact Factor

Full-text (2 Sources)

Available from
May 16, 2014